Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Journal of Southern Medical University ; (12): 1240-1242, 2009.
Article in Chinese | WPRIM | ID: wpr-336101

ABSTRACT

<p><b>OBJECTIVE</b>To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia.</p><p><b>METHODS</b>A total of 110 NYHA class II-III patients with CHF complicated by ventricular arrhythmia were randomly divided into amiodarone group, metoprolol group and amiodarone + metoprolol group. The therapeutic effects was evaluated at the end of the 1-year follow-up.</p><p><b>RESULTS</b>Amiodarone, metoprolol and their combination produced statistically different therapeutic effects (P<0.05). Compared with amiodarone and metoprolol used alone, amiodarone combined with metoprolol resulted in significant cardiac function improvement (P<0.05) and ventricular arrhythmia control (P<0.01). During the 1-year follow-up, the readmission rate and cardiac event rate in the amiodarone + metoprolol group were significantly lower than those in amiodarone group (P<0.01) and metoprolol group (P<0.05). The adverse reaction rates in the 3 groups were similar (P>0.05).</p><p><b>CONCLUSION</b>The combination of amiodarone and metoprolol produces better effect than amiodarone or metoprolol alone in the treatment of CHF complicated by ventricular arrhythmia.</p>


Subject(s)
Adult , Female , Humans , Male , Adrenergic beta-Antagonists , Therapeutic Uses , Amiodarone , Therapeutic Uses , Anti-Arrhythmia Agents , Therapeutic Uses , Chronic Disease , Drug Therapy, Combination , Heart Failure , Drug Therapy , Metoprolol , Therapeutic Uses , Tachycardia, Ventricular , Drug Therapy , Treatment Outcome , Ventricular Premature Complexes , Drug Therapy
2.
Journal of Zhejiang University. Medical sciences ; (6): 31-38, 2009.
Article in Chinese | WPRIM | ID: wpr-310394

ABSTRACT

<p><b>OBJECTIVE</b>To develop a novel gene delivery vector with poly-aspartamide-glutamic acid and polyethylenimine as the backbone.</p><p><b>METHODS</b>alpha, beta-poly-(N-2-hydroxypropyl)-D, L-aspartamide-glutamic acid (PHPAG) was synthesized and low molecular weight polyethylenimine (PEI 1.8 kDa) was grafted to form PHPAG-PEI 1800. Chemical and biological characterization of the polymer was identified.</p><p><b>RESULT</b>The polymer was confirmed by (1)H-NMR, and the molecular weight was about 1.2 x 10(4). The ability of DNA binding was showed by gel retardation assay at N/P ratio of 3. 5. MTT assay showed that the polymer was non toxic in COS-7 and A293 cell lines. In vitro test demonstrated that it had high transfection efficiency in B16 and Hela cell lines.</p><p><b>CONCLUSION</b>PHPAG-PEI 1800 was successfully synthesized,which might be a potential vector for gene delivery.</p>


Subject(s)
Humans , Cell Line , Gene Transfer Techniques , Genetic Therapy , Methods , Glutamic Acid , Chemistry , Peptides , Chemistry , Polyethyleneimine , Chemistry
SELECTION OF CITATIONS
SEARCH DETAIL